Gemcitabine in advanced angiosarcoma: A retrospective case series analysis from the Italian rare cancer network

S. Stacchiotti, E. Palassini, R. Sanfilippo, B. Vincenzi, M. G. Arena, A. M. Bochicchio, P. De Rosa, A. Nuzzo, S. Turano, C. Morosi, A. P. Dei Tos, S. Pilotti, P. G. Casali

Research output: Contribution to journalArticle


Background: Angiosarcoma is a highly aggressive soft tissue sarcoma. Responses to anthracyclines plus/minus ifosfamide, and taxanes alone or in combination with gemcitabine are well documented. Very few data are available on gemcitabine as a single agent. Patients and methods: We retrospectively reviewed all cases of advanced progressive angiosarcoma treated with gemcitabine as a single agent (1000 mg/m. 2 i.v. every week for 3 weeks every 4 weeks), at Istituto Nazionale Tumori and within the Italian Rare Cancers Network from January 2008 to November 2010. Results: Twenty-five patients [mean age: 52 years; radiation therapy (RT)-related: 8] received gemcitabine. Best tumor response by RECIST was as follows: complete response = 2, partial response = 14, stable disease = 2, progressive disease = 7 cases, for an overall response rate (PR + CR) of 68%. Six of eight post-RT angiosarcomas responded to treatment. Median overall survival (OS) was 17 months. Median progression-free survival (PFS) was 7 months (range 1-40 months). One patient with a locally advanced thyroid angiosarcoma became resectable after 5 months of gemcitabine, with

Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalAnnals of Oncology
Issue number2
Publication statusPublished - Feb 2012



  • Angiosarcoma
  • Chemotherapy
  • Gemcitabine
  • Sarcoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this